Literature DB >> 10527804

Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.

F Persichetti1, F Trettel, C C Huang, C Fraefel, H T Timmers, J F Gusella, M E MacDonald.   

Abstract

Huntington's disease (HD) is caused by an expanded glutamine tract, which confers a novel aggregation-promoting property on the 350-kDa huntingtin protein. Using specific antibodies, we have probed the structure of the polyglutamine segment in mutant huntingtin complexes formed in cell culture from either truncated or full-length protein. Complexes formed by a mutant amino terminal fragment most frequently entail a change in conformation that eliminates reactivity with the polyglutamine-specific mAb 1F8, coincident with production of insoluble aggregate. By contrast, complexes formed by the full-length mutant protein remain soluble and are invariably 1F8-reactive, indicating a soluble polyglutamine conformation. Therefore, aggregates in HD may form by different biochemical mechanisms that invoke different possibilities for the pathogenic process. If pathogenesis is triggered by a truncated fragment, it probably involves the formation of an insoluble aggregate. However, the observation of soluble complexes in which an HD-specific pathogenic conformation of the glutamine tract remains accessible suggests that pathogenesis could also be triggered at the level of full-length huntingtin by abnormal aggregation with normal or abnormal protein partners. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527804     DOI: 10.1006/nbdi.1999.0260

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  16 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  A structural model of polyglutamine determined from a host-guest method combining experiments and landscape theory.

Authors:  John M Finke; Margaret S Cheung; José N Onuchic
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

Review 3.  The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.

Authors:  James R Arndt; Maxmore Chaibva; Justin Legleiter
Journal:  Biomol Concepts       Date:  2015-03

4.  The Structural Properties in Solution of the Intrinsically Mixed Folded Protein Ataxin-3.

Authors:  Alessandro Sicorello; Geoff Kelly; Alain Oregioni; Jiří Nováček; Vladimír Sklenář; Annalisa Pastore
Journal:  Biophys J       Date:  2018-07-03       Impact factor: 4.033

5.  An ovine transgenic Huntington's disease model.

Authors:  Jessie C Jacobsen; C Simon Bawden; Skye R Rudiger; Clive J McLaughlan; Suzanne J Reid; Henry J Waldvogel; Marcy E MacDonald; James F Gusella; Simon K Walker; Jennifer M Kelly; Graham C Webb; Richard L M Faull; Mark I Rees; Russell G Snell
Journal:  Hum Mol Genet       Date:  2010-02-13       Impact factor: 6.150

6.  Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.

Authors:  Kurt R Weiss; Yoko Kimura; Wyan-Ching Mimi Lee; J Troy Littleton
Journal:  Genetics       Date:  2011-11-17       Impact factor: 4.562

7.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.

Authors:  Thomas Heister; Irma Heid; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  A linear lattice model for polyglutamine in CAG-expansion diseases.

Authors:  Melanie J Bennett; Kathryn E Huey-Tubman; Andrew B Herr; Anthony P West; Scott A Ross; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

9.  Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein and promotes its atypical ubiquitination to enhance aggregate formation.

Authors:  Silvia Zucchelli; Federica Marcuzzi; Marta Codrich; Elena Agostoni; Sandra Vilotti; Marta Biagioli; Milena Pinto; Alisia Carnemolla; Claudio Santoro; Stefano Gustincich; Francesca Persichetti
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

10.  Huntingtin facilitates polycomb repressive complex 2.

Authors:  Ihn Sik Seong; Juliana M Woda; Ji-Joon Song; Alejandro Lloret; Priyanka D Abeyrathne; Caroline J Woo; Gillian Gregory; Jong-Min Lee; Vanessa C Wheeler; Thomas Walz; Robert E Kingston; James F Gusella; Ronald A Conlon; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.